Ageless Biotech, Inc. has acquired an Open Label Phase IIb Study to Evaluate Safety and Tolerability of OA-SYS in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint with plans to start Clinical Trails in March 2022.